Clinical efficacy of transcatheter arterial chemoembolization combined with lenvatinib and camrelizumab in the treatment of advanced hepatocellular carcinoma
10.3969/j.issn.1008-794X.2024.01.011
- VernacularTitle:经导管动脉化疗栓塞联合仑伐替尼及卡瑞利珠单抗治疗中晚期肝细胞癌临床效果
- Author:
Xuexian ZHANG
1
;
Yuhan DING
;
Wei LI
;
Qingwei LI
;
Jun ZHANG
;
Dan DUAN
;
Yongle LI
;
Jian LONG
;
Jidong YANG
;
Chenglong ZHANG
;
Peng WU
;
Huijuan SUN
;
Geng WU
Author Information
1. 448000 湖北荆门荆门市人民医院血管介入科
- Keywords:
transcatheter arterial chemoembolization;
lenvatinib;
camrelizumab;
hepatocellular carcinoma;
curative effect;
safety
- From:
Journal of Interventional Radiology
2024;33(1):57-62
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the safety and efficacy of transcatheter arterial chemoembolization(TACE)combined with lenvatinib and camrelizumab in the treatment of advanced hepatocellular carcinoma(HCC).Methods The clinical data of a total of 63 patients with advanced HCC,who received TACE combined with lenvatinib and camrelizumab(triple therapy)or TACE combined with lenvatinib(dual therapy)at the Jingmen Municipal People's Hospital of China between April 2020 and December 2021,were retrospectively analyzed.Triple therapy group had 30 patients,and dual therapy group had 33 patients.The post-treatment tumor response,disease progression-free survival(PFS),overall survival(OS),and the incidence of adverse drug reactions were recorded.Results The median follow-up period of the two groups was 14 months(range of 4-26 months).Compared with the dual therapy group,in the triple therapy group the objective response rate(ORR)was remarkably higher(83.3%vs.57.6%,P=0.026),the disease control rate(DCR)was obviously higher(93.3%vs.69.7%,P=0.039),the median PFS was significantly longer(8.0 months vs.5.0 months,P＜0.01),and the median OS was strikingly longer(24.0 months vs.12.0 months,P=0.004).No statistically significant difference in the incidence of adverse drug reactions existed between the two groups(P＞0.05).Conclusion For the treatment of advanced HCC,TACE combined with lenvatinib and camrelizumab is clinically safe and effective.(J Intervent Radiol,2024,32:57-62)
